UK inflation unexpectedly eases in December, which could reduce pressure in bond markets
Body count from South African mine siege rises to 60
US importers rush in goods from China as Trump tariff threat looms
Novak Djokovic breaks a tie with Roger Federer for the most Grand Slam matches in tennis history
China's RedNote: what you need to know about the app TikTok users are flocking to
British author Neil Gaiman denies ever engaging in non-consensual sex as more accusers come forward
(Reuters) - Medical device maker Dexcom on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more than 11% higher in extended trading.
Quarterly sales rose 27% to $975 million, surpassing analysts' estimates of $939.24 million, according to LSEG data.
Larger peer Abbott had also posted strong sales of $1.4 billion for its CGM system, FreeStyle Libre, in diabetes care.
CGM systems track blood sugar levels throughout the day and can transmit glucose readings as frequently as five minutes.
Dexcom raised its annual revenue forecast to between $3.58 billion and $3.6 billion, compared with its previous range of $3.5 billion to $3.55 billion. Analysts expect annual sales of $3.55 billion.
Excluding items, the company posted a profit of 50 cents for the quarter ended Sept. 30, compared with estimates of 35 cents.
Shares of the California-based company rose to $90 after the bell.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath)
